BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.

For the first time, Stanford University researchers have used a new type of whole genome sequencing to diagnose a patient.

Scientists at Pfizer have figured out how to make blood cancer cells more vulnerable to attack—by driving them from their favorite hiding place.

Biotech stocks are enjoying their most buoyant patch in months, after reports President Trump's crackdown on pricing may not be as tough as feared.

ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.

Eli Lilly has completed the expansion of its biotech facility in San Diego, California. The $90 million expansion has added 180,000 square feet to the 125,000-…

Repare Therapeutics has emerged from stealth mode with an impressive $68 million.

Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.

Theranos and Walgreens have reached a tentative agreement to put the latter's breach-of-contract lawsuit to rest, WSJ sources say.

Sarepta Therapeutics has penned its second DMD gene therapy pact this year.